An EphA2-targeting Bicycle® Drug Conjugate (BDC®), nuzefatide pevedotin, in combination with nivolumab in patients with advanced solid tumors: results from a Phase 1/2 study

We use cookies and other technologies to optimise your experience and analyse our traffic. Please confirm you are happy to accept. You can change your preferences in “Cookie Settings”.